Transcript Consorzio Interuniversitario Nazionale per la Bio

The Mediterranean School of Oncology
56th course
“Breast Cancer:
from Epidemiology to Treatment”
Tunis, November 14, 2008
The Mediterranean School of Oncology
An educational program of:
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
A Consortium of 15 Italian Universities
32 Full Professors,
55 Associate
Professors
Ancona
Ferrara
Napoli Federico II
95 Scientists
Bologna
Palermo
Foggia
Campus Biomedico
L’Aquila
15 Cancer Clinics
Catanzaro
Chieti-Pescara
12.000 sqm
Perugia
Milano
Roma La Sapienza
Messina Teramo
laboratories
2 Clinical Trial Offices
Tumor Registry & Screening Programs
www.cinbo.org
Two classes:
1. Italian residents
2. Foreign students (in English);
All courses are accredited for ECM by Ministero della Salute, Italy or/and
ESMO
10
Courses/year
8
Students/year
6
47 courses
>2500 students
300
2
0
500
400
4
By December 2007:
600
200
2001
2002 2003 2004 2005 2006 2007
0
1954 78
75
72
35
30
25
20
15
10
5
Students by country
A large spectrum of cancer-related
disciplines is covered, including:
Molecular pathology & cancer genetics
Onco-hemathology
Medical oncology
Radiation oncology
Epidemiology/ biostatistics & clinical trials
Cancer prevention & early diagnosis
…..
Educational program
•
Postgraduate courses;
•
Training courses for health professionals
not frequently dealing with cancer patients;
•
Special topics for oncology nurses;
•
Master classes (residential, 2-weeks, with
practical workshops) (Coming soon)
Scholarships
Available to candidates <30 years of age.
To apply for a scholarship:
• a brief curriculum vitae;
• a letter of presentation from an authorised
officer at the institute of affiliation.
For information:
http://www.mso.cinbo.org/
Diapo avaible a partir du
24 novembre prochaine:
http://www.mso.cinbo.org/
A Consortium of 15 Italian Universities
Ancona
Bologna
Campus Biomedico
Catanzaro
Chieti-Pescara
Ferrara
Milano
Messina
Napoli Federico II
Palermo
Perugia
Foggia
Roma La Sapienza
L’Aquila
Teramo
2008 – Course calendar
March 3-4*
Digestive cancers: from epidemiology to management
March 28-29
Assessing and managing toxicities of molecularly targeted agents
April 11-12
Highlights in management of gastrointestinal cancer
May 9-10
Highlights in the management of prostate cancer
June 13-14
Highlights in the management of NSCL cancer
July 4-5
Highlights in the management of breast cancer
September 26-27
Highlights in management of kidney cancer
October
16-18
to be defined
October 23-26
to be defined
November 7-8
to be defined
November 28-29
*Cairo, Egypt
Translational oncology: novel agents, approaches and targets
The “Formazione a Distanza in
Oncologia” (FADO) Program
A MSO/CINBO’s pilot project
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
FADO Program
Designed to build or enhance professional
knowledge, skills, and leadership in oncology
and related disciplines through distance/online
education & training.
Teaching is made via
satellite technology.
Target audience
1. Residents in medical oncology;
2. Ph.D. students (Dottorato di Ricerca)
in oncology and related disciplines
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
FADO - Partners
Organization & management:
Technologies & services:
QuickTime™ e un
de com press ore TIFF (LZW)
so no n ece ssari per vi sual izzare q uest'im magi ne.
The Mediterranean Task Force
for Cancer Control (MTCC)
A MSO/CINBO’s pilot project
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
MTCC
“An innovative project to raise awareness
about cancer prevention and early detection
via satellite technology”
• courses
• videoconferences;
• lectures-seminars-lessons;
To provide a forum for
“distance learning discussion among CINBO
member Universities and selected medical
Institutions within the mediterranean area”
Launching Meeting of the Mediterranean Task Force for
Cancer Prevention and Early Detection (MTCC)
February 2nd, 2007
Rome, Italy
With the participation of delegates from:
Albania
Algeria
Croatia
Egypt
France
Italy
Jordan
Lebanon
Lybia
Morocco
Portugal
Syria
Slovenia
Spain
Tunisia
Greece
Palestine
Turkey
Axel Ullrich
Pioneer in signal transduction & cancer research
Cloned human insulin gene licensed to Eli Lilly
Discovered EGFR, HER2, FLK-1 etc
Architect of targeted therapeutics
One of the first scientists at Genentech
Responsible for Herceptin – annual sales ca. >$1.0BN
Discoveries led to SUTENT – projected sales >$1.0BN
Director of Max Planck Society
Founder of SUGEN Inc.
NASDAQ listed in 1994
Sold to Pharmacia in 1997 for $670m